Overactive BladderPhase 4NCT00928070
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
A Phase 4 study testing Fesoterodine in people with Overactive Bladder, run by Pfizer at 125 sites in United States.
Trial summary
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB). Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Overactive Bladder
- What is being tested?
- Fesoterodine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 566 participants
- Where
- 125 sitesUnited States
- Study dates
- Sep 2009to Sep 2011
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- male or female subjects 65 years of age or older
- OAB symptoms for at least 3 months
- score 3 or greater on Vulnerable Elderly Survey (VES-13)
- adequate mobility for independent toileting
- mean number of at least 2 UUI episodes per 24 hours
- mean urinary frequency of 8 or more micturitions per 24 hours
- able to independently complete the bladder diaries
Who cannot join
- PVR urinary volume greater than 200 ml
- MMSE score less than 20
- greater than 15 UUI episodes per 24 hours
- creatinine clearance less than 30 ml/min
- an average resting heart rate of greater than or equal to 90 beats per minute
Trial locations and contacts
125 sites in 1 country.
125 sites in 1 country
United States125 sites
Pfizer Investigational Site
Albany, New York, 12208
Pfizer Investigational Site
Altoona, Pennsylvania, 16602
Pfizer Investigational Site
Arkansas City, Kansas, 67005
Pfizer Investigational Site
Atlanta, Georgia, 30067
Pfizer Investigational Site
Aurora, Colorado, 80012
Pfizer Investigational Site
Austin, Texas, 78745
Pfizer Investigational Site
Austin, Texas, 78757
Pfizer Investigational Site
Baltimore, Maryland, 21211
Pfizer Investigational Site
Bethany, Oklahoma, 73008
Pfizer Investigational Site
Birmingham, Alabama, 35233
Pfizer Investigational Site
Birmingham, Alabama, 35294
Pfizer Investigational Site
Bonita Springs, Florida, 34134
Pfizer Investigational Site
Boynton Beach, Florida, 33472
Pfizer Investigational Site
Bristol, Tennessee, 37620
Pfizer Investigational Site
Brooklyn, New York, 11215
Pfizer Investigational Site
Brooksville, Florida, 34601
Pfizer Investigational Site
Burien, Washington, 98166
Pfizer Investigational Site
Cary, North Carolina, 27511
Pfizer Investigational Site
Cary, North Carolina, 27518
Pfizer Investigational Site
Charleston, South Carolina, 29425
Pfizer Investigational Site
Chattanooga, Tennessee, 37404
Pfizer Investigational Site
Clearwater, Florida, 33756
Pfizer Investigational Site
Colorado Springs, Colorado, 80907
Pfizer Investigational Site
Colorado Springs, Colorado, 80909
Pfizer Investigational Site
Columbia, South Carolina, 29201
Pfizer Investigational Site
Corpus Christi, Texas, 78414
Pfizer Investigational Site
Costa Mesa, California, 92626
Pfizer Investigational Site
Daytona Beach, Florida, 32114
Pfizer Investigational Site
DeLand, Florida, 32720
Pfizer Investigational Site
Denver, Colorado, 80211
Pfizer Investigational Site
Denver, Colorado, 80220
Pfizer Investigational Site
East Providence, Rhode Island, 02914
Pfizer Investigational Site
East Providence, Rhode Island, 02915
Pfizer Investigational Site
Edina, Minnesota, 55435
Pfizer Investigational Site
Englewood, Colorado, 80110
Pfizer Investigational Site
Englewood, Colorado, 80113
Pfizer Investigational Site
Erie, Pennsylvania, 16507
Pfizer Investigational Site
Fairfield, California, 94534
Pfizer Investigational Site
Fort Lauderdale, Florida, 33316
Pfizer Investigational Site
Glen Burnie, Maryland, 21061
Pfizer Investigational Site
Glendora, California, 91741
Pfizer Investigational Site
Grand Rapids, Michigan, 49503
Pfizer Investigational Site
Green Valley, Arizona, 85614
Pfizer Investigational Site
Groton, Connecticut, 06340
Pfizer Investigational Site
Houston, Texas, 77062
Pfizer Investigational Site
Houston, Texas, 77074
Pfizer Investigational Site
Jackson, Tennessee, 38305
Pfizer Investigational Site
Kalamazoo, Michigan, 49009
Pfizer Investigational Site
Kansas City, Kansas, 66160-7390
Pfizer Investigational Site
La Mesa, California, 91942
Pfizer Investigational Site
Lake Worth, Florida, 33461
Pfizer Investigational Site
Las Vegas, Nevada, 89119
Pfizer Investigational Site
Leander, Texas, 78641
Pfizer Investigational Site
Lexington, Kentucky, 40503
Pfizer Investigational Site
Lexington, Kentucky, 40504
Pfizer Investigational Site
Lincoln, Nebraska, 68516
Pfizer Investigational Site
Little Rock, Arkansas, 72204
Pfizer Investigational Site
Little Rock, Arkansas, 72223
Pfizer Investigational Site
Long Beach, California, 90806
Pfizer Investigational Site
Longmont, Colorado, 80501
Pfizer Investigational Site
Longview, Texas, 75601
Pfizer Investigational Site
Longview, Texas, 75605
Pfizer Investigational Site
Macon, Georgia, 31217
Pfizer Investigational Site
Melbourne, Florida, 32901
Pfizer Investigational Site
Memphis, Tennessee, 38119
Pfizer Investigational Site
Mesa, Arizona, 85206-1734
Pfizer Investigational Site
Milford, Connecticut, 06460
Pfizer Investigational Site
Mission Viejo, California, 92691
Pfizer Investigational Site
Montgomery, Alabama, 36117
Pfizer Investigational Site
Moorestown, New Jersey, 08057
Pfizer Investigational Site
Murray, Utah, 84107
Pfizer Investigational Site
Murrieta, California, 92562
Pfizer Investigational Site
Myrtle Beach, South Carolina, 29572
Pfizer Investigational Site
Naples, Florida, 34102
Pfizer Investigational Site
New London, Connecticut, 06320
Pfizer Investigational Site
New Port Richey, Florida, 34652
Pfizer Investigational Site
New Port Richey, Florida, 34655
Pfizer Investigational Site
Newburgh, Indiana, 47630
Pfizer Investigational Site
Norman, Oklahoma, 73069
Pfizer Investigational Site
Norwalk, California, 90650
Pfizer Investigational Site
Ocala, Florida, 34471
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73109
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112
Pfizer Investigational Site
Omaha, Nebraska, 68114
Pfizer Investigational Site
Paramount, California, 90723
Pfizer Investigational Site
Parker, Colorado, 80134
Pfizer Investigational Site
Phoenix, Arizona, 85032
Pfizer Investigational Site
Picayune, Mississippi, 39466
Pfizer Investigational Site
Pittsburgh, Pennsylvania, 15243
Pfizer Investigational Site
Plant City, Florida, 33563
Pfizer Investigational Site
Portland, Oregon, 97205
Pfizer Investigational Site
Raleigh, North Carolina, 27612
Pfizer Investigational Site
Rancho Santa Margarita, California, 92688
Pfizer Investigational Site
Richmond, Virginia, 23229
Pfizer Investigational Site
Salt Lake City, Utah, 84103
Pfizer Investigational Site
San Antonio, Texas, 78216
Pfizer Investigational Site
San Antonio, Texas, 78229
Pfizer Investigational Site
San Bernardino, California, 92404
Pfizer Investigational Site
San Diego, California, 92108
Pfizer Investigational Site
Santa Ana, California, 92705
Pfizer Investigational Site
Sarasota, Florida, 34237
Pfizer Investigational Site
Sewell, New Jersey, 08080
Pfizer Investigational Site
Shreveport, Louisiana, 71106
Pfizer Investigational Site
Southaven, Mississippi, 38671
Pfizer Investigational Site
Spokane, Washington, 99216
Pfizer Investigational Site
Springfield, Illinois, 62702
Pfizer Investigational Site
Springfield, Illinois, 62703
Pfizer Investigational Site
Springfield, Massachusetts, 01103
Pfizer Investigational Site
St Louis, Missouri, 63117
Pfizer Investigational Site
St. Petersburg, Florida, 33710
Pfizer Investigational Site
Staten Island, New York, 10304
Pfizer Investigational Site
Temecula, California, 92591
Pfizer Investigational Site
Temple, Texas, 76508
Pfizer Investigational Site
Towson, Maryland, 21204
Pfizer Investigational Site
Trinity, Florida, 34655
Pfizer Investigational Site
Tucson, Arizona, 85712
Pfizer Investigational Site
Tuscon, Arizona, 85710
Pfizer Investigational Site
Vacaville, California, 95688
Pfizer Investigational Site
Wellington, Florida, 33449
Pfizer Investigational Site
West Jordan, Utah, 84088
Pfizer Investigational Site
Wichita, Kansas, 67205
Pfizer Investigational Site
Wichita, Kansas, 67207
Pfizer Investigational Site
Williamsville, New York, 14221
Pfizer Investigational Site
Willoughby Hills, Ohio, 44094
Pfizer Investigational Site
Winter Haven, Florida, 33880
About this study
Official title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Conditions
- Overactive Bladder
- Being tested
- Fesoterodine, Placebo
- Keywords
- Urgency Urinary Incontinence OAB
- Medical subject headings
- Urinary Bladder, Overactive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FesoterodineDrug
Fesoterodine 4 mg and 8 mg
PlaceboDrug
Placebo sham 4 mg and 8 mg
| Study group | Role | What they receive |
|---|---|---|
| Fesoterodine | Experimental | Not described Receives: Drug: Fesoterodine |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours
UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12
UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Week 12
Secondary outcomes (24)
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4
UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Week 4
Percent Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12
Percent change of UUI episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).
Measured: Baseline, Week 4, 12
Mean Number of Micturitions Per 24 Hours
Micturitions include episodes of voluntary micturition and episodes of UUI. UUI episodes were defined as those micturitions with USS rating of 5 in the diary in participants with UUI at baseline. USS rating 5: Unable to hold; leak urine.
Measured: Baseline
Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4 and 12
Micturitions include episodes of voluntary micturition and episodes of UUI. UUI episodes were defined as those micturitions with USS rating of 5 in the diary in participants with UUI at baseline. USS rating 5: Unable to hold; leak urine.
Measured: Baseline, Week 4, 12
Percent Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12
Percent change of micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).
Measured: Baseline, Week 4, 12
Mean Number of Micturition-related Urgency Episodes Per 24 Hours
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (>=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline
Change From Baseline in Mean Number of Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (>=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Week 4, 12
Percent Change From Baseline in Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12
Percent change of micturition-related urgency episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).
Measured: Baseline, Week 4, 12
Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours
Nocturnal micturition-related urgency episodes had USS rating of 3 or more that occurred between time participant went to bed and time he or she arose to start next day. Number of nocturnal micturition-related urgency episodes per 24 hours was calculated as sum of all nocturnal micturition-related urgency episodes divided by total number of diary days collected at that visit.
Measured: Baseline
Change From Baseline in Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12
Nocturnal micturition-related urgency episodes had USS rating of 3 or more that occurred between time participant went to bed and time he or she arose to start next day. Number of nocturnal micturition-related urgency episodes per 24 hours was calculated as sum of all nocturnal micturition-related urgency episodes divided by total number of diary days collected at that visit.
Measured: Baseline, Week 4, 12
Percent Change From Baseline in Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12
Percent change of nocturnal micturition-related urgency episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).
Measured: Baseline, Week 4, 12
Frequency-Urgency Sum Rating Per 24 Hours
Frequency-urgency sum is total USS ratings recorded for all micturitions in 24-hour day. Number of USS ratings per 24 hours is sum of all USS ratings divided by the total diary days collected at that visit. USS scale: 1=No feeling of urgency to 5=Unable to hold: leak urine.
Measured: Baseline
Change From Baseline in Frequency-Urgency Sum Rating Per 24 Hours at Week 4 and 12
Frequency-urgency sum is total USS ratings recorded for all micturitions in 24-hour day. Number of USS ratings per 24 hours is sum of all USS ratings divided by the total diary days collected at that visit. USS scale: 1=No feeling of urgency to 5=Unable to hold: leak urine. Numerical decrease indicates improvement.
Measured: Baseline, Week 4, 12
Change From Baseline in Mean Number of Protective Undergarments Changed Due to Urinary Leakage Per 24 Hours at Week 4 and 12
Protective Undergarments included pads, protective padding, protective underwear (pull up), and briefs (diaper). The mean number of undergarments changed per 24 hours was calculated as the total number of undergarments changed divided by the total number of diary days collected at that visit. Change from baseline values were reported at week 4 for subsets of population with baseline values less than or equal to (=<) 3.5 and more than (>) 3.5 undergarments/day and at Week 12 for subsets of population with baseline values =< 2.5 and > 2.5 undergarments/day.
Measured: Baseline, Week 4, 12
Percentage of Participants With Change From Screening in Patient Perception of Bladder Condition (PPBC) at Week 4 and 12
PPBC: a self-administered, single-item, questionnaire that asks participants to describe their perception of their bladder-related problems. The PPBC assessment is rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Deterioration=score difference is greater than 0; no change=score difference is 0; minor improvement=score difference is -1; major difference=score difference is less than or equal to -2.
Measured: Screening, Week 4, 12
Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.
Measured: Baseline
Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 4 and 12
OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.
Measured: Baseline, Week 4, 12
Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q)
OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.
Measured: Baseline
Change From Baseline in Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 4 and 12
OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.
Measured: Baseline, Week 4, 12
Overactive Bladder Satisfaction Questionnaire (OAB-S) Total Score on Satisfaction With OAB Control
OAB-S: a validated self-administered instrument that evaluates OAB medication expectations, daily life with AB, and satisfaction with OAB medication and includes 3 stand-alone items that assess overall expectation, satisfaction, and willingness to continue treatment. Satisfaction coded on scale of 1 to 5: (1=very satisfied to 5=very dissatisfied). Coding reversed algorithmically and results transformed: total score range 0 to100. Higher final response value associated with better satisfaction.
Measured: Week 12
Percentage of Participants With Overactive Bladder Satisfaction Questionnaire (OAB-S) Global Medication Satisfaction Question Response
Participant's response to question, "overall, how satisfied are you with your OAB medication?" was obtained on a 5 point scale, 1- very satisfied, 2- somewhat satisfied, 3- neither dissatisfied nor satisfied, 4- somewhat dissatisfied and 5- very dissatisfied. Response values 1 and 2 were combined into "satisfied", and 4 and 5 were combined into "dissatisfied".
Measured: Week 12
Mini Mental State Examination (MMSE)
MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranges from 0 to 30, higher score indicates better cognitive state.
Measured: Screening
Change From Screening in Mini Mental State Examination (MMSE) Score at Week 12
MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranges from 0 to 30, higher score indicates better cognitive state. Change: mean score at Week X minus mean score at baseline
Measured: Screening, Week 12
Change From Baseline in Post Void Residual (PVR) Volume at Week 4 and 12
PVR volume is defined as volume of urine remaining in the bladder immediately after urination.
Measured: Baseline, Week 4, 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2009 (estimated)
- Study startSep 2009
- Primary completionSep 2011
- Study completionSep 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Overactive BladderStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 566 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00928070
- Sponsor's protocol ID
- A0221049
- Status last verified
- Dec 2012
- First submitted
- 24 Jun 2009
- Last updated
- 17 Jan 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.
PubMed 37160401Dubeau CE, Kraus SR, Griebling TL, Newman DK, Wyman JF, Johnson TM 2nd, Ouslander JG, Sun F, Gong J, Bavendam T. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014 Feb;191(2):395-404. doi: 10.1016/j.juro.2013.08.027. Epub 2013 Aug 21.
PubMed 23973522
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.
- ClinicalTrials.gov ID
- NCT00928070
- Acronym / sponsor ID
- A0221049
- Conditions
- Overactive Bladder
- Keywords
- Urgency Urinary Incontinence OAB
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 566 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Sep 2009
- Primary completion
- Sep 2011 (actual)
- Study completion
- Sep 2011 (actual)
- First posted
- 25 Jun 2009 (estimated)
- Results
- Posted 17 Jan 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fesoterodine | Experimental | Drug: Fesoterodine |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (7 listed)
- male or female subjects 65 years of age or older
- OAB symptoms for at least 3 months
- score 3 or greater on Vulnerable Elderly Survey (VES-13)
- adequate mobility for independent toileting
- mean number of at least 2 UUI episodes per 24 hours
Key exclusion criteria (5 listed)
- PVR urinary volume greater than 200 ml
- MMSE score less than 20
- greater than 15 UUI episodes per 24 hours
- creatinine clearance less than 30 ml/min
- an average resting heart rate of greater than or equal to 90 beats per minute
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FesoterodineFesoterodine 4 mg and 8 mg | Drug | Fesoterodine |
| PlaceboPlacebo sham 4 mg and 8 mg | Drug | Placebo |
Primary outcome
Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours
Time frame: Baseline
UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12
Time frame: Baseline, Week 12
UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
24 secondary outcomes
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4
Time frame: Baseline, Week 4
Percent Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Mean Number of Micturitions Per 24 Hours
Time frame: Baseline
Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Percent Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Mean Number of Micturition-related Urgency Episodes Per 24 Hours
Time frame: Baseline
Change From Baseline in Mean Number of Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Percent Change From Baseline in Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours
Time frame: Baseline
Change From Baseline in Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Percent Change From Baseline in Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Frequency-Urgency Sum Rating Per 24 Hours
Time frame: Baseline
Change From Baseline in Frequency-Urgency Sum Rating Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Change From Baseline in Mean Number of Protective Undergarments Changed Due to Urinary Leakage Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4, 12
Percentage of Participants With Change From Screening in Patient Perception of Bladder Condition (PPBC) at Week 4 and 12
Time frame: Screening, Week 4, 12
Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
Time frame: Baseline
Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 4 and 12
Time frame: Baseline, Week 4, 12
Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q)
Time frame: Baseline
Change From Baseline in Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 4 and 12
Time frame: Baseline, Week 4, 12
Overactive Bladder Satisfaction Questionnaire (OAB-S) Total Score on Satisfaction With OAB Control
Time frame: Week 12
Percentage of Participants With Overactive Bladder Satisfaction Questionnaire (OAB-S) Global Medication Satisfaction Question Response
Time frame: Week 12
Mini Mental State Examination (MMSE)
Time frame: Screening
Change From Screening in Mini Mental State Examination (MMSE) Score at Week 12
Time frame: Screening, Week 12
Change From Baseline in Post Void Residual (PVR) Volume at Week 4 and 12
Time frame: Baseline, Week 4, 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37160401Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.
- Derived from this study: PubMed 23973522Dubeau CE, Kraus SR, Griebling TL, Newman DK, Wyman JF, Johnson TM 2nd, Ouslander JG, Sun F, Gong J, Bavendam T. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014 Feb;191(2):395-404. doi: 10.1016/j.juro.2013.08.027. Epub 2013 Aug 21.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Overactive Bladder
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
Active, not recruitingObservational study
Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
RecruitingObservational study
Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder
Overactive Bladder (OAB)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
125 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Fesoterodine in people with Overactive Bladder, run by Pfizer at 125 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 125 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00928070, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2013.